PCM
SPRY icon

Permanent Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Permanent Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$290K Sell
35,115
-17,191
-33% -$165K 0.05% 123
2025
Q4 		$609K Sell
52,306
-1,035
-2% -$10.1K 0.12% 77
2025
Q3 		$536K Buy
+53,341
New +$766K 0.1% 81
2024
Q2 		$744K Buy
+42,623
New +$378K 0.16% 65

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Permanent Capital Management's SPRY Position: Q1 2026 in Review

Permanent Capital Management reduced its ARS Pharmaceuticals (SPRY) stake by 33% in Q1 2026, selling an estimated $165K and leaving 35,115 shares worth $290K. The position accounts for 0.05% of the portfolio, ranked #123.

Permanent Capital Management first reported a position in SPRY in Q2 2024 and has held it in 4 quarters since. The position peaked at $744K in Q2 2024. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Permanent Capital Management held 35,115 shares of ARS Pharmaceuticals worth $290K as of Q1 2026.
  • Permanent Capital Management sold 17,191 ARS Pharmaceuticals shares in Q1 2026, an estimated $165K.
  • ARS Pharmaceuticals made up 0.05% of Permanent Capital Management's portfolio in Q1 2026, its #123 holding.
  • Permanent Capital Management first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
  • Permanent Capital Management's ARS Pharmaceuticals position peaked at $744K in Q2 2024.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Permanent Capital Management's 13F filing for Q1 2026, filed 14 May 2026.